Patents by Inventor Pamela L. Dunn
Pamela L. Dunn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7166289Abstract: The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an inclusion membrane protein C of a strain of Chlamydia pneumoniae and a promoter to effect expression of the inclusion membrane protein C gene in the host.Type: GrantFiled: January 14, 2004Date of Patent: January 23, 2007Assignee: Sanofi Pasteur LimitedInventors: Andrew D. Murdin, Pamela L. Dunn, Raymond P. Oomen
-
Patent number: 6872814Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an 98 kDa putative outer membrane protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the 98 kDa putative outer membrane protein gene in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: October 27, 1999Date of Patent: March 29, 2005Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn
-
Publication number: 20040228874Abstract: The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an inclusion membrane protein C of a strain of Chlamydia pneumoniae and a promoter to effect expression of the inclusion membrane protein C gene in the host.Type: ApplicationFiled: January 14, 2004Publication date: November 18, 2004Inventors: Andrew D. Murdin, Pamela L. Dunn, Raymond P. Oomen
-
Patent number: 6811783Abstract: A protective immune response against Chlamydial infection is achieved by in vivo administration of an immunogenic composition comprising two vectors and a pharmaceutically-acceptable carrier therefor. One of the vectors comprises a first nucleotide sequence encoding a major outer membrane protein (MOMP) of a strain of Chlamydia, preferably C. pneumoniae, and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The other of the vectors comprises a second nucleotide sequence encoding a 76 kDa protein of a strain of Chlamydia, preferably C. pneumoniae, and a promoter sequence operatively coupled to the second nucleotide sequence for expression of the 76 kDa protein in the host. The protection efficiency which is achieved by the immunization procedure is enhanced over that attained with the individual vectors alone.Type: GrantFiled: September 7, 1999Date of Patent: November 2, 2004Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Pamela L. Dunn
-
Patent number: 6693087Abstract: An isolated and purified nucleic acid molecule encoding a POMP91A protein of a strain of Chlamydia, is useful for nucleic acid immunization of a host, including a human host, against disease caused by infection by a strain of Chlamydia, particularly C. pneumoniae.Type: GrantFiled: August 20, 1999Date of Patent: February 17, 2004Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Pamela L. Dunn, Raymond P. Oomen
-
Publication number: 20040022801Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an POMP91B precursor protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the POMP91B precursor gene in the host. Modifications are possible within the scope of this invention.Type: ApplicationFiled: January 28, 2003Publication date: February 5, 2004Inventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn
-
Patent number: 6686339Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a inclusion membrane protein C of a strain of Chlamydia pneumoniae and a promoter to effect expression of the inclusion membrane protein C gene in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: June 15, 2001Date of Patent: February 3, 2004Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Pamela L. Dunn, Raymond P. Oomen
-
Patent number: 6660275Abstract: The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a CPN100605 polypeptide of a strain of Chlamydia pneumoniae and a promoter to effect expression of the CPN100605 polypeptide in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: July 26, 1999Date of Patent: December 9, 2003Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn
-
Patent number: 6649370Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an 98 kDa outer membrane protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the 98 kDa outer membrane protein gene in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: October 26, 1999Date of Patent: November 18, 2003Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn
-
Patent number: 6642025Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a lorf2 protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the lorf2 gene in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: July 13, 2001Date of Patent: November 4, 2003Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn
-
Publication number: 20030170259Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an 98 kDa putative outer membrane protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the 98 kDa putative outer membrane protein gene in the host. Modifications are possible within the scope of this invention.Type: ApplicationFiled: October 27, 1999Publication date: September 11, 2003Applicant: MINTZ, LEVIN, COHEN, FERRIS, GLOVSKY, POPEOInventors: ANDREW D. MURDIN, RAYMOND P. OOMEN, PAMELA L. DUNN
-
Patent number: 6607730Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an POMP91B precursor protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the POMP91B precursor gene in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: October 29, 1999Date of Patent: August 19, 2003Assignee: Aventis Pasteur Limited/Aventis Pasteur LimiteeInventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn
-
Patent number: 6521745Abstract: An isolated and purified nucleic acid molecule encoding an inclusion membrane protein C of a strain of Chlamydia, is useful for nucleic acid immunization of a host, including a human host, against disease caused by infection by a strain of Chlamydia, particularly C. pneumoniae.Type: GrantFiled: August 20, 1999Date of Patent: February 18, 2003Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Pamela L. Dunn, Raymond P. Oomen
-
Publication number: 20020150591Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a CPN100605 polypeptide of a strain of Chlamydia pneumoniae and a promoter to effect expression of the CPN100605 polypeptide in the host. Modifications are possible within the scope of this invention.Type: ApplicationFiled: July 26, 1999Publication date: October 17, 2002Applicant: MINTZ, LEVIN, COHEN, FERRIS, GLOVSKY & POPEO, P.C.Inventors: ANDREW D. MURDIN, RAYMOND P. OOMEN, PAMELA L. DUNN
-
Publication number: 20020102270Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an 98 kDa outer membrane protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the 98 kDa outer membrane protein gene in the host. Modifications are possible within the scope of this invention.Type: ApplicationFiled: February 8, 2001Publication date: August 1, 2002Inventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn
-
Publication number: 20020091096Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a lorf2 protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the lorf2 gene in the host. Modifications are possible within the scope of this invention.Type: ApplicationFiled: July 13, 2001Publication date: July 11, 2002Inventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn
-
Patent number: 6403101Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a lorf2 protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the lorf2 gene in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: October 26, 1999Date of Patent: June 11, 2002Assignee: Connaught Laboratories LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn
-
Patent number: 6403102Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an PilG-like protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the PilG-like gene in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: October 27, 1999Date of Patent: June 11, 2002Assignee: Connaught Laboratories LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn